A SPAC III Acquisition Corp.(ASPC) - 2025 Q1 - Quarterly Report

Financial Position - As of March 31, 2025, total assets amounted to $62,249,731, a slight increase from $62,075,158 as of December 31, 2024[11] - Total current liabilities decreased significantly from $517,334 as of December 31, 2024, to $278,705 as of March 31, 2025[11] - Total shareholders' equity decreased from $3,863,392 as of December 31, 2024, to $2,904,104 as of March 31, 2025[11] - As of March 31, 2025, the Company had $1,119,610 in cash and working capital of $982,030, with liquidity needs previously satisfied through a $25,000 sale of Founders Shares and a $350,000 loan from the Sponsor[39] - As of March 31, 2025, the Company had $1,119,610 in cash and $60,988,996 in investments held in the Trust Account, compared to $1,598,890 and $60,356,959 respectively as of December 31, 2024[50][54] Income and Expenses - The company reported a net income of $413,202 for the three months ended March 31, 2025, compared to no income reported for the same period in 2024[12] - For the three months ended March 31, 2025, the Company reported a net income of $413,202, consisting of interest income of $647,080, offset by general and administrative expenses of $233,878[110] - The Company reported general and administrative expenses of $233,878 for the three months ended March 31, 2025[100] - Interest earned on investments held in the Trust Account was $632,037 for the three months ended March 31, 2025[100] IPO and Financing - The IPO generated total gross proceeds of $55,000,000 from the sale of 5,500,000 units at an offering price of $10.00 per unit[25] - The Company incurred $1,600,217 in transaction costs related to the IPO, including $600,000 in underwriting fees[114] - The Sponsor purchased 280,000 private placement units at a price of $10.00 per unit for a total of $2,800,000 simultaneously with the IPO[73] - The underwriter partially exercised the over-allotment option on November 19, 2024, purchasing 500,000 Units, generating gross proceeds of $5,000,000[83] - The Company completed its IPO on November 12, 2024, raising gross proceeds of $55 million from the sale of 5,500,000 units at $10.00 per unit[140] Business Combination - The Company has not commenced any operations and will not generate operating revenues until after completing its initial Business Combination[23] - The Company has 12 months (or up to 18 months if extended) to complete its initial Business Combination, or it will cease operations and liquidate[34] - The Company may need additional financing to complete its Business Combination or to redeem public shares, which could involve issuing more securities or incurring debt[40] - If the Company cannot complete a Business Combination by November 12, 2025, it will liquidate, raising substantial doubt about its ability to continue as a going concern[41] - The Company intends to effectuate its initial business combination using cash from the IPO proceeds and other financing methods[104] Acquisitions - The aggregate consideration for the acquisition of HD Group is $300,000,000, to be paid entirely in stock at a price of $10.00 per share[37] - The aggregate consideration for the acquisition of Bioserica is $200,000,000, also to be paid entirely in stock at a price of $10.00 per share[38] Risks and Uncertainties - Various global political and economic uncertainties may adversely affect the Company's ability to consummate a Business Combination[42] - The ongoing conflicts and market volatility may impact the Company's ability to raise necessary financing for its operations and Business Combination[43] - The Company expects to incur significant costs to remain a publicly traded company and pursue a Business Combination, raising substantial doubt about its ability to continue as a going concern[119] Shareholder Information - Basic and diluted net income per share for Class A ordinary shares subject to possible redemption was $0.11 for the three months ended March 31, 2025[12] - Class A ordinary shares subject to possible redemption were valued at $59,066,922 as of March 31, 2025, an increase from $57,694,432 as of December 31, 2024[56] - The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination on a one-for-one basis[89] - As of March 31, 2025, the Company had 550,000 Class A ordinary shares outstanding, excluding 6,000,000 Class A ordinary shares subject to possible redemption[87] Accounting and Compliance - The Company is classified as an "emerging growth company" and has opted not to comply with certain reporting requirements applicable to non-emerging growth companies[46] - The Company follows the asset and liability method for accounting for income taxes, with no income tax provision due to its status in the British Virgin Islands[63] - The fair value of the Company's financial instruments approximates their carrying amounts due to their short-term nature[59] - The Company has not recognized any unrecognized tax benefits or accrued interest and penalties as of March 31, 2025[62] - The Company has evaluated its disclosure controls and procedures and concluded they were effective at a reasonable assurance level as of March 31, 2025[134] Other Information - The Company has no outstanding borrowings under Working Capital Loans as of March 31, 2025[79] - The Company has no long-term debt or off-balance sheet arrangements as of March 31, 2025[120] - The Company has granted the underwriter a right of first refusal for future equity offerings for 12 months following the closing of a Business Combination[82] - The Company adopted ASU 2023-09 on January 1, 2025, which requires expanded disclosures of income taxes paid, with no significant impact reported[69] - The funds in the Trust Account will be invested only in U.S. government treasury bills or money market funds meeting specific conditions[144]